2. Membrane Transporter/Ion Channel
  3. Piezo Channel
  4. Dooku1

Dooku1 is a reversibly Yoda1 antagonist with IC50 value of 1.3 μM and 1.5 μM for 2 μM Yoda1-induced Ca2+ entry HEK 293 cells and HUVECs, respectively. Dooku1 can disrupt Yoda1-induced Piezo1 channel activity and inhibit Yoda1-induced relaxation of aorta. Dooku1 can be used for vascular physiology and disease research.

For research use only. We do not sell to patients.

CAS No. : 2253744-54-4

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 16 publication(s) in Google Scholar

Dooku1 Related Antibodies

Top Publications Citing Use of Products

    Dooku1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 16;17(1):272.  [Abstract]

    The addition of Dooku-1 markedly abrogated Ca2+ influx induced by US stimulation and significantly inhibited US-triggered active caspase-1 release in DCs.

    Dooku1 purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Dec 3:36:102620.  [Abstract]

    Pre-treatment with Dooku1 slowed the rate of spheroid formation.

    Dooku1 purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Dec 3:36:102620.  [Abstract]

    IF staining confirmed the on-target activity of Dooku1, as it significantly suppressed the Yoda1 (0.5 μM)-induced upregulation of Piezo1 itself

    Dooku1 purchased from MedChemExpress. Usage Cited in: ACS Appl Mater Interfaces. 2025 Feb 5;17(5):7363-7376.  [Abstract]

    Dooku1 inhibits shear-stress-induced NLRP3 inflammasome activation in iBMDMs. (A) A representative imaging panel is shown above for ASC−CFP expressed iBMDMs primed LPS for 4 h followed by treatments of 10 or 50 μM Dooku1 for 2 h and 50 dyn/cm2 shear stress treatment for 30 min. LPS only controls were also performed according to aforementioned time points. NucRed stains living cell nuclei in blue, ASC−CFP specks indicating inflammasome activation are shown in cyan, and propidium iodide (PI) shows dead cell nuclei in red.

    Dooku1 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Jan 28;44(1):115136.  [Abstract]

    The pharmacological inhibition of Piezo1 (by Dooku1 (2 μM) and GsMTx4) in mouse T cells reduced IL-9 production and altered SIRT3, SDHA, and HIF1α expression.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Dooku1 is a reversibly Yoda1 antagonist with IC50 value of 1.3 μM and 1.5 μM for 2 μM Yoda1-induced Ca2+ entry HEK 293 cells and HUVECs, respectively. Dooku1 can disrupt Yoda1-induced Piezo1 channel activity and inhibit Yoda1-induced relaxation of aorta. Dooku1 can be used for vascular physiology and disease research[1].

    In Vitro

    Dooku1 (10 μM, 300 s) has selectivity for Piezo1 channels in HEK 293 and CHO cells.[1].
    Dooku1 (10 μM, 140 s) has no effect on constitutive Piezo1 channel activity in Piezo1 T-REx cells[1].
    Dooku1 (10 μM, 40-60 s) inhibits endogenous Yoda1-activated channels in HUVECs and Piezo1 T-REx cells[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Dooku1 Related Antibodies

    Cell Viability Assay[1]

    Cell Line: HUVECs, Piezo1 T-REx cells
    Concentration: 10 μM
    Incubation Time: 40-60 s
    Result: Had a concentration-dependent inhibitory effect against Yoda1-induced Ca2+ entry in HUVECs, acting with an IC50 of 1.49 μM.
    Increased potency in HUVECs with an EC50 of 0.23 μM, compared with 2.51 μM in Piezo1 T-REx cells.
    In Vivo

    Dooku1 (10 μM incubate 20 min) selectively inhibits Yoda1-induced relaxation of aorta of wild-type male C57BL/6 mice[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: wild-type male C57BL/6 mice’s aortic rings[1]
    Dosage: 10 μM
    Administration: 20 min
    Result: Suppressed the Yoda1-induced relaxation.
    Molecular Weight

    326.20

    Formula

    C13H9Cl2N3OS
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    ClC1=C(C(Cl)=CC=C1)CSC2=NN=C(C3=CC=CN3)O2
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    -20°C, sealed storage, away from moisture

    *In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (306.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.0656 mL 15.3280 mL 30.6560 mL
    5 mM 0.6131 mL 3.0656 mL 6.1312 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.08 mg/mL (6.38 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.93%

    SDS (394 KB)

    COA (250 KB) HNMR (255 KB) RP-HPLC (244 KB) LCMS (96 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.0656 mL 15.3280 mL 30.6560 mL 76.6401 mL
    5 mM 0.6131 mL 3.0656 mL 6.1312 mL 15.3280 mL
    10 mM 0.3066 mL 1.5328 mL 3.0656 mL 7.6640 mL
    15 mM 0.2044 mL 1.0219 mL 2.0437 mL 5.1093 mL
    20 mM 0.1533 mL 0.7664 mL 1.5328 mL 3.8320 mL
    25 mM 0.1226 mL 0.6131 mL 1.2262 mL 3.0656 mL
    30 mM 0.1022 mL 0.5109 mL 1.0219 mL 2.5547 mL
    40 mM 0.0766 mL 0.3832 mL 0.7664 mL 1.9160 mL
    50 mM 0.0613 mL 0.3066 mL 0.6131 mL 1.5328 mL
    60 mM 0.0511 mL 0.2555 mL 0.5109 mL 1.2773 mL
    80 mM 0.0383 mL 0.1916 mL 0.3832 mL 0.9580 mL
    100 mM 0.0307 mL 0.1533 mL 0.3066 mL 0.7664 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Dooku1 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Dooku12253744-54-4Dooku 1Dooku-1Piezo ChannelYoda1HEK 293HUVECsvascular physiologyInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Dooku1
    Cat. No.:
    HY-126010
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (394 KB) Français - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Español - ES (394 KB) Swedish - SV (394 KB) Italian - IT (394 KB) Korean - KR (394 KB) Portuguese - PT (394 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.